The term derives from the Greek pharmakon (drug) and dynamis (power or force). Pharmacodynamics encompasses the study of receptor binding, dose–response relationships, signal transduction, and the molecular and physiological consequences of a substance's interaction with its biological target. It is conventionally paired with pharmacokinetics, which describes absorption, distribution, metabolism, and excretion.
Central to pharmacodynamic analysis is the concept of the dose–response curve: a graphical representation of the relationship between the amount of a substance administered and the magnitude of the measured effect. Key parameters derived from this curve include the maximum effect (Emax), the half-maximal effective concentration (EC50), and the Hill coefficient, which describes the steepness of the sigmoidal curve. These values are used to characterise potency and efficacy across different compounds.
Pharmacodynamic interactions between substances are classified as additive (effects sum to expected totals), synergistic (combined effect exceeds the sum of individual effects), or antagonistic (one substance diminishes the effect of another). Understanding these interactions is foundational to evaluating multi-compound preparations, including plant-based and cannabinoid formulations, where multiple bioactive constituents may act simultaneously at overlapping or distinct receptor sites.
In the Australian regulatory context, pharmacodynamic data form part of the evidence base required for product registration with the Therapeutic Goods Administration (TGA). Under the Therapeutic Goods Act 1989 (Cth), sponsors seeking to register a medicine on the Australian Register of Therapeutic Goods (ARTG) must submit nonclinical and clinical data , including pharmacodynamic studies , that substantiate quality, safety, and efficacy claims as assessed against the relevant TGA guidelines.
Sources: